Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors
- PMID: 24956462
- DOI: 10.1016/j.ejps.2014.06.003
Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors
Abstract
A new series of 29 diarylpyrimidine analogues featuring a cyclopropylamino group between the pyrimidine scaffold and the aryl wing have been synthesized. All of the new compounds have been characterized by spectra analysis. The target molecules were evaluated for their in vitro anti-HIV activity with FDA-approved drugs as references. Some of the compounds exhibited moderate to potent activities against wild-type HIV-1. The compound 4-((4-((cyclopropylamino)(2,5-difluorophenyl)methyl)pyrimidin-2-yl)amino)benzonitrile (1e) displayed potent anti-HIV-1 activity against WT HIV-1 with an IC50 of 0.099 μM and a selectivity index of 2302. The preliminary structure-activity relationship (SAR) of this new series of compounds was also investigated.
Keywords: Anti-HIV activity; Cyclopropylamine; Cyclopropylamine (PubChem CID: 24847670); Diarylpyrimidine; Non-nucleoside RT inhibitors; SAR.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.Eur J Med Chem. 2014 Jul 23;82:600-11. doi: 10.1016/j.ejmech.2014.05.059. Epub 2014 Jun 5. Eur J Med Chem. 2014. PMID: 24952305
-
Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.Bioorg Med Chem. 2010 Apr 1;18(7):2370-4. doi: 10.1016/j.bmc.2010.03.007. Epub 2010 Mar 9. Bioorg Med Chem. 2010. PMID: 20307984
-
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.Eur J Med Chem. 2013 Jul;65:134-43. doi: 10.1016/j.ejmech.2013.04.052. Epub 2013 May 3. Eur J Med Chem. 2013. PMID: 23707918
-
[Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].Yao Xue Xue Bao. 2010 Feb;45(2):177-83. Yao Xue Xue Bao. 2010. PMID: 21351427 Review. Chinese.
-
Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.Curr Med Chem. 2011;18(16):2376-85. doi: 10.2174/092986711795843209. Curr Med Chem. 2011. PMID: 21568919 Review.
Cited by
-
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years.Acta Pharm Sin B. 2020 Jun;10(6):961-978. doi: 10.1016/j.apsb.2019.11.010. Epub 2019 Nov 21. Acta Pharm Sin B. 2020. PMID: 32642405 Free PMC article. Review.
-
Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors.Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619826265. doi: 10.1177/2040206619826265. Antivir Chem Chemother. 2019. PMID: 30788976 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous